Twenty years after its founding, the Auvergne-Rhône-Alpes health cluster Lyonbiopôle has unveiled a tightened strategy for 2025–2029, designed to address mounting pressures on French medtech and biotech startups: surging Chinese competition, risk-averse investors, and mounting drug-pricing scrutiny.

Launched in 2005 around infectious diseases, the “gold”-labelled cluster now brings together 260 members—from startups and labs to giants like Sanofi, bioMérieux and Boehringer Ingelheim—and a broader ecosystem of over 600 players. Its new roadmap, “Du sens à l’impact,” narrows its focus from six strategic areas to three: prevention and precision health (vaccines, screening, tailored therapies); food systems and One Health (human, animal and environmental health); and industrial innovation and health production (novel manufacturing processes to make devices and drugs faster and better). The “tools and technologies” and “neurosciences” domains have been dropped.

President Hervé Gisserot describes a “third, much harder phase” where funding is tighter and projects must be more mature and market-oriented. He flags stark Chinese competition: medical device makers produce at scale and low cost—quality gaps are closing fast—while Chinese labs can develop a high-quality mRNA drug candidate in nine months versus three years in Europe, thanks not to skills but to resources and societal acceptance. Meanwhile, venture capital is flowing toward defence, AI and fintech, and the drug-pricing debate, fuelled by the US Inflation Reduction Act, threatens innovation if final prices aren’t viable.

The strategy sets five impact ambitions, including protection against infectious risks, better diagnostics to fight antimicrobial resistance, faster access to innovations, and bolstering health sovereignty. A flagship move: a post-summer “bioproduction club” to connect and showcase around 100 regional players spanning the entire drug value chain—an asset unique to the region in France. On the funding front, the cluster will beef up matchmaking, fundraising assistance and strategic support to help startups scale, and will push for Bpifrance’s future deep-tech scale-up fund to include firms older than ten years, because, Gisserot stresses, “breakthrough innovation takes time—it doesn’t happen in five or seven years.”

Lyonbiopôle will deepen ties with neighbouring clusters (Minalogic, Axelera, Techtera) and regional structures, and is expanding its 14-strong team with hires in marketing/communications and partnerships. The roadmap will be formalised through a forthcoming agreement with the French state and regional authorities.

Vingt ans après sa création, le pôle de compétitivité santé de la région Auvergne-Rhône-Alpes, Lyonbiopôle a dévoilé, mi-juin, sa nouvelle feuille de route visant à mieux répondre aux nouveaux défis qui frappent les medtechs et biotechs françaises. Parmi eux : une concurrence chinoise en plein essor, des investisseurs plus frileux face aux risques, mais aussi le prix des médicaments.